We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Novo Nordisk Bank of America, Netflix, Johnson & Johnson and TotalEnergies
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 22, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novo Nordisk A/S (NVO - Free Report) , Bank of America Corporation (BAC - Free Report) , Netflix, Inc. (NFLX - Free Report) , Johnson & Johnson (JNJ - Free Report) and TotalEnergies SE (TTE - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Novo Nordisk, Bank of America and Netflix
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S, Bank of America Corporation and Netflix, Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Novo Nordisk have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+81.2% vs. +11.7%). The company beat earnings and revenue estimates in Q3 due to higher GLP-1 product sales. It has one of the broadest diabetes portfolios in the industry. Ozempic and Rybelsus have been performing well in the diabetes market.
Obesity drug Wegovy has been enjoying increasing demand. Label expansions of diabetes and obesity care drugs in cardiovascular and other indications will likely boost sales. Novo Nordisk raised its 2023 view due to higher demand for Ozempic and Wegovy. Its diversifying efforts to develop new treatments are encouraging.
However, stiffer competition from pharma bigwigs like Pfizer, who are likely to eat away from Novo Nordisk's Diabetes care market share due to serious supply constraints in international markets. Patent expiry and pricing pressure across the diabetes market also remain a woe.
Shares of Bank of America have gained +7.6% over the past six months against the Zacks Banks - Major Regional industry's gain of +9.9%. The company's third-quarter 2023 results reflect higher revenues and costs. Because of inflationary pressure, overall costs are expected to remain elevated.
The current tough macroeconomic outlook might weigh on the company's investment banking (IB) business. This, along with the volatile nature of the capital markets, might hurt non-interest income growth.
Despite these headwinds, we believe that higher rates and decent loan demand will keep aiding the company's net interest income (NII) growth, which the Zacks analyst expects to grow 8.5% this year. The opening of financial centers and improving digital capabilities is expected to further aid the top line.
Shares of Netflix have outperformed the Zacks Broadcast Radio and Television industry over the past year (+65.5% vs. +29.3%). The company is benefiting from growing subscriber base thanks to a robust portfolio. Crackdown on password-sharing and the introduction of paid sharing in more than 100 countries, which represents more than 80% of Netflix's revenue base, is also expected to aid growth.
Netflix's diversified content portfolio, which is attributable to heavy investments in the production and distribution of localized, foreign-language content, has been driving its growth prospects.
However, stiff competition in the streaming space from the likes of Apple, Amazon Prime Video, Disney+, Peacock and Paramount+ is a headwind. Netflix's leveraged balance sheet and a higher streaming obligation are concerns. Additionally, unfavorable forex is expected to hurt operating income in the fourth quarter of 2023.
Other noteworthy reports we are featuring today include Johnson & Johnson and TotalEnergies SE.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Novo Nordisk Bank of America, Netflix, Johnson & Johnson and TotalEnergies
For Immediate Release
Chicago, IL – November 22, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novo Nordisk A/S (NVO - Free Report) , Bank of America Corporation (BAC - Free Report) , Netflix, Inc. (NFLX - Free Report) , Johnson & Johnson (JNJ - Free Report) and TotalEnergies SE (TTE - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Novo Nordisk, Bank of America and Netflix
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S, Bank of America Corporation and Netflix, Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Novo Nordisk have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+81.2% vs. +11.7%). The company beat earnings and revenue estimates in Q3 due to higher GLP-1 product sales. It has one of the broadest diabetes portfolios in the industry. Ozempic and Rybelsus have been performing well in the diabetes market.
Obesity drug Wegovy has been enjoying increasing demand. Label expansions of diabetes and obesity care drugs in cardiovascular and other indications will likely boost sales. Novo Nordisk raised its 2023 view due to higher demand for Ozempic and Wegovy. Its diversifying efforts to develop new treatments are encouraging.
However, stiffer competition from pharma bigwigs like Pfizer, who are likely to eat away from Novo Nordisk's Diabetes care market share due to serious supply constraints in international markets. Patent expiry and pricing pressure across the diabetes market also remain a woe.
(You can read the full research report on Novo Nordisk here >>>)
Shares of Bank of America have gained +7.6% over the past six months against the Zacks Banks - Major Regional industry's gain of +9.9%. The company's third-quarter 2023 results reflect higher revenues and costs. Because of inflationary pressure, overall costs are expected to remain elevated.
The current tough macroeconomic outlook might weigh on the company's investment banking (IB) business. This, along with the volatile nature of the capital markets, might hurt non-interest income growth.
Despite these headwinds, we believe that higher rates and decent loan demand will keep aiding the company's net interest income (NII) growth, which the Zacks analyst expects to grow 8.5% this year. The opening of financial centers and improving digital capabilities is expected to further aid the top line.
(You can read the full research report on Bank of America here >>>)
Shares of Netflix have outperformed the Zacks Broadcast Radio and Television industry over the past year (+65.5% vs. +29.3%). The company is benefiting from growing subscriber base thanks to a robust portfolio. Crackdown on password-sharing and the introduction of paid sharing in more than 100 countries, which represents more than 80% of Netflix's revenue base, is also expected to aid growth.
Netflix's diversified content portfolio, which is attributable to heavy investments in the production and distribution of localized, foreign-language content, has been driving its growth prospects.
However, stiff competition in the streaming space from the likes of Apple, Amazon Prime Video, Disney+, Peacock and Paramount+ is a headwind. Netflix's leveraged balance sheet and a higher streaming obligation are concerns. Additionally, unfavorable forex is expected to hurt operating income in the fourth quarter of 2023.
(You can read the full research report on Netflix here >>>)
Other noteworthy reports we are featuring today include Johnson & Johnson and TotalEnergies SE.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.